Iman Imanirad, MD

Cancer Focus:
Appendiceal (Appendix) Cancer, Colorectal Cancer, Peritoneal Cancer

Dr. Iman Imanirad is an Assistant Member at Moffitt Cancer Center. He is also a Professor of Oncology at the University of South Florida College of Medicine. Dr. Imanirad received his medical degree from Saba University School of Medicine and completed his residency at the University of Florida where he also completed three years of hematology oncology fellowship. After completing his fellowship, he worked as a medical Oncologist and hematologist at Tallahassee Memorial Hospital to fulfill the requirements for a J1 visa. During his fellowship, Dr. Imanirad was the recipient of several awards such as Most Outstanding Fellow Award and Fellow of the Year Award. He was also awarded the Moffitt High Performer Award in 2019. Dr. Imanirad’s clinical and research interests focus on gastrointestinal tumors, in particular Colon, Appendiceal and Peritoneal cancers. He is a principal investigator of a phase II study of TAS-102. He has been published in many peer reviewed journals including Clinical Colorectal Cancer and Journal of Gastrointestinal Cancer. Dr. Imanirad has recently been contracted as an expert disease site contributor with MyCareGorithm.

Education & Training

Board Certification:

• Internal Medicine - Hematology
• Internal Medicine - Medical Oncology

Fellowship:

• University of Florida College of Medicine - Hematology Oncology

Residency:

• University of Florida College of Medicine - Internal Medicine

Medical School:

• Saba University of Medical Sciences - MD

Clinical Trial 21336
A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (Intrinsic)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Bevicizumab (); Cetuximab (); Divarasib (); Erbitux (Cetuximab); FOLFIRI (); FOLFOX (); GDC-6036 (); Inavolisib (); Oxaliplatin (); SY-5609 (); Tiragolumab (); eloxatin (Oxaliplatin); leucovorin ()
Status: Open

Clinical Trial 21459
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); CAPOX (); CPT-11 (irinotecan); Camptosar (irinotecan); FOLFIRINOX (); FOLFOX6 (); Oxaliplatin (); Xeloda (capecitabine); capecitabine (); eloxatin (Oxaliplatin); irinotecan (); leucovorin ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Odeh A, Saleh D, Bayer R, Johnston DR, Imanirad I, Al-Kazaz M. Cardiac Septal Metastasis From Poorly Differentiated Colorectal Adenocarcinoma: A Rare Case Illustrating the Role of Multimodal Imaging and Multidisciplinary Management. Case Rep Cardiol. 2025 Nov.2025:6626317. Pubmedid: 41362832. Pmcid: PMC12682442.
• Yu J, Laborde JM, Park R, Shahzad M, Kim Y, Cheon J, Imanirad I, Kim RD, Biachi de Castria T, Nardella NL, Malafa M, Denbo JW, Fleming JB, Hoffe SE, Frakes JM, Sinnamon AJ, Pimiento JM, Hodul PJ, Kim DW. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507279. Pmcid: PMC12153592.
• Hendrick LE, Naffouje S, Imanirad I, Pereira AL, Biachi T, Sanchez J, Dessureault S, Stefanou A, Dineen SP, Felder S. Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity-Matched Analysis. J Surg Oncol. 2025 May.131(6):1090-1100. Pubmedid: 39658830.
• Park MA, Jacobson R, Genilo-Delgado M, Mohammadi A, Moran-Segura C, Alhassan S, Nakanishi Y, Permuth JB, Imanirad I, Dineen SP. The Transcriptomic Landscapes of Appendiceal Primary and Metastatic Tumors are Distinct. Ann Surg Oncol. 2025 May.32(5):3660-3671. Pubmedid: 39987388.
• Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clin Pharmacol Ther. 2025 May.117(5):1194-1208. Pubmedid: 39887719. Pmcid: PMC11993294.
• Hendrick LE, Felder S, Imanirad I, Dineen SP. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is NOT a Last Resort: Rationale for Early Surgical Referral. JCO Oncol Pract. 2025 Apr.21(4):454-457. Pubmedid: 39418624.
• Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, Levine R, Parker AS, Swain SM, Tillman EM, Hicks JK. Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566. Cancers (Basel). 2024 Oct.16(21). Pubmedid: 39518158. Pmcid: PMC11544884.
• Boland PM, Mukherjee S, Imanirad I, Vijayvergia N, Cohen SD, Gupta M, Iyer RV, Bakin A, Wang J, Chatley S, Cahill B, Vadehra D, Attwood K, Hochster HS, Fountzilas C. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. Brit J Cancer. 2024 Nov.131(8):1290-1297. Pubmedid: 39244627. Pmcid: PMC11473817.
• Yu J, Park R, Miao R, Imanirad I, Shahzad M, Laborde JM, Knepper TC, Walko CM, Kim R. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors. J Immunother. 2024 Nov.47(9):378-383. Pubmedid: 39012081.
• Kim DW, Kim YC, Kovari BP, Martinez M, Miao R, Yu J, Mehta R, Strosberg J, Imanirad I, Kim RD. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers (Basel). 2024 Jan.16(3). Pubmedid: 38339307. Pmcid: PMC10854756.
• Pointer DT, Felder SI, Powers BD, Dessureault S, Sanchez JA, Imanirad I, Sahin I, Xie H, Naffouje SA. Return to intended oncologic therapy after colectomy for stage III colon adenocarcinoma: Does surgical approach matter?. Colorectal Dis. 2023 Sep.25(9):1760-1770. Pubmedid: 37553808.
• Liu J, Wang X, Sahin IH, Imanirad I, Felder SI, Kim RD, Xie H. Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. Am J Clin Oncol. 2023 Feb.46(2):50-57. Pubmedid: 36606664.
• Read M, Powers BD, Pimiento JM, Laskowitz D, Mihelic E, Imanirad I, Dessureault S, Felder S, Dineen SP. Management of Malignant Small Bowel Obstruction: Is Intestinal Bypass Effective Palliation?. Ann Surg Oncol. 2022 Oct.29(11):6980-6987. Pubmedid: 35864366.
• Read M, Powers BD, Pimiento JM, Laskowitz D, Mihelic E, Imanirad I, Dessureault S, Felder S, Dineen SP. ASO Visual Abstract: Management of Malignant Small Bowel Obstruction-Is Intestinal Bypass Effective Palliation?. Ann Surg Oncol. 2022 Oct.29(11):6990. Pubmedid: 35913671.
• Tan E, Whiting J, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Walko C, Permuth JB, Sommerer K, Kim R, Anaya DA, Fleming JB, Sahin IH. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. Oncologist. 2022 Mar.27(3):191-197. Pubmedid: 35274712. Pmcid: PMC8914499.
• Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul.169:93-102. Pubmedid: 35526308.
• Naffouje SA, Manguso N, Imanirad I, Sahin IH, Xie H, Hoffe S, Frakes J, Sanchez J, Dessureault S, Felder S. Neoadjuvant rectal score is prognostic for survival: A population-based propensity-matched analysis. J Surg Oncol. 2022 Dec.126(7):1219-1231. Pubmedid: 35916542.
• Mills MN, Naz A, Sanchez J, Dessureault S, Imanirad I, Lauwers G, Moore M, Hoffe S, Frakes J, Felder S. Rectal tumor fragmentation as a response pattern following chemoradiation. J Gastrointest Oncol. 2022 Dec.13(6):2951-2962. Pubmedid: 36636056. Pmcid: PMC9830359.
• Mehta R, Frakes J, Kim J, Nixon A, Liu Y, Howard L, Martinez Jimenez ME, Carballido E, Imanirad I, Sanchez J, Dessureault S, Xie H, Felder S, Sahin I, Hoffe S, Malafa M, Kim R. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist. 2022 Aug.27(8):621-e617. Pubmedid: 35325225. Pmcid: PMC9355805.
• Tan E, Whiting J, Knepper T, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Permuth JB, Somerer K, Kim R, Anaya DA, Fleming JB, Walko C, Sahin IH. Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. Am J Clin Oncol. 2022 Apr.45(4):137-141. Pubmedid: 35320814.
• Naffouje S, Sabesan A, Powers BD, Dessureault S, Sanchez J, Schell M, Imanirad I, Sahin I, Xie H, Felder S. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021 Sep.20(3):e155-e164. Pubmedid: 33775560.
• McDonald J, Chuang CY, Hicks JK, Berry DK, Imanirad I, Rishi A, Frakes JM, Hoffe SE, Felder S. FANCD2 Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. Adv Radiat Oncol. 2021 May.6(5):100717. Pubmedid: 34258475. Pmcid: PMC8260782.
• Bigness A, Imanirad I, Sahin IH, Xie H, Frakes J, Hoffe S, Laskowitz D, Felder S. Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation. CA-Cancer J Clin. 2021 May.71(3):198-208. Pubmedid: 33592118.
• Felder SI, Feuerlein S, Parsee A, Imanirad I, Sanchez J, Dessureault S, Kim R, Hoffe S, Frakes J, Costello J. Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. Abdom Radiol (NY). 2021 May.46(5):1783-1804. Pubmedid: 33111189.
• Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Brit J Cancer. 2021 May.124(11):1803-1808. Pubmedid: 33828254. Pmcid: PMC8144213.
• Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, Levine R, Parker AS, Swain SM, Tillman EM, Hicks JK. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel). 2021 Mar.13(7). Pubmedid: 33805415. Pmcid: PMC8036652.
• Powers BD, Felder SI, Imanirad I, Dessureault S, Dineen SP. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis. J Gastrointest Cancer. 2021 Jun.52(2):719-727. Pubmedid: 32743731.
• Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
• Dhahri A, Kaplan J, Naqvi SMH, Brownstein NC, Ntiri SO, Imanirad I, Felder SI, Dineen SP, Sanchez J, Dessureault S, Carballido E, Powers BD. The impact of socioeconomic status on survival in stage III colon cancer patients: A retrospective cohort study using the SEER census-tract dataset. Cancer Med. 2021 Aug.10(16):5643-5652. Pubmedid: 34197047. Pmcid: PMC8366079.
• Yuan Z, Frazer M, Ahmed KA, Naqvi SMH, Schell MJ, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Torres-Roca JF, Hoffe SE, Frakes JM. Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncol. 2020 Oct.16(30):2411-2420. Pubmedid: 32686956.
• Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, Imanirad I, Carballido E, Kim RD, Hoffe SE, Frakes JM. Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. Am J Clin Oncol. 2020 May.43(5):319-324. Pubmedid: 32028341.
• Yuan Z, Frazer M, Zhang GG, Latifi K, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Frakes JM. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. J Med Imaging Radiat Oncol. 2020 Jun.64(3):444-449. Pubmedid: 32386109.
• Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol. 2020 Dec.27(13):4883-4891. Pubmedid: 32318945.
• Cogle CR, Iannacone MR, Yu D, Cole AL, Imanirad I, Yan L, Mackinnon JA, List AF, Rollison DE. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res. 2014 Jan.38(1):71-75. Pubmedid: 24280283.
• Dallas J, Imanirad I, Rajani R, Dagan R, Subbiah S, Gaa R, Dwarica WA, Ivey AM, Zlotecki RA, Malyapa R, Indelicato DJ, Scarborough MT, Reith JD, Gibbs CP, Dang LH. Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report. J Med Case Rep. 2012 Jan.6:41. Pubmedid: 22289277. Pmcid: PMC3277477.
• Imanirad I, Rajasekhar A, Zumberg M. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher. 2012 Aug.27(4):221-226. Pubmedid: 22467376.
• Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH. Combination therapy for renal cell cancer: what are possible options?. Oncology-Basel. 2012 Apr.81(3-4):220-229. Pubmedid: 22085914. Pmcid: PMC3225259.
• Cogle CR, Imanirad I, Wiggins LE, Hsu J, Brown R, Scornik JC, Wingard JR. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol. 2010 Jan.8(1):40-46. Pubmedid: 20351682.